Cogent Biosciences, Inc. (COGT) Stock: Price, Forecast & Analyst Target
Cogent Biosciences, Inc. (COGT) — MoonshotScore 50/100 (Fair band), calculated Nov 18, 2026. Price $27.74 (-0.25%), as of the Nov 19, 2026 trading session; market cap $4.83B.
Educational signal · not a buy or sell recommendation · How to read this
Cogent Biosciences, Inc. · COGT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Cogent Biosciences is a clinical-stage biotechnology company developing targeted therapies for genetic mutations that drive blood and gastrointestinal cancers, with its lead candidate in late-stage trials. The central question is whether the lead program advances to regulatory approval and commercial launch, generating revenue that transitions the company from burn-rate dependent to cash-generative; if the program fails, cash runway becomes the critical metric.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cogent Biosciences (COGT)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and a full valuation, though the balance sheet is only middling. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.
- EPS beat 0 of the last 4 reports
- Altman Z 5.99 · Piotroski F 2
- ROE -99.6% · ROA -42.0% · current ratio 10.99
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 51 | Fair | |
| 51 | Fair | |
| 50 | Fair | |
| 50 | Fair | |
| 50 | Fair | |
| 50 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $27.74 | |
| Change on the day | -0.25% | |
| 52-week range | $26.46–$43.73 | |
| Market capitalisation | $4.83B | — |
| Price / earnings (trailing) | -37.99 | |
| Shares traded on the day | 1.68M | |
| Beta (volatility vs the S&P 500) | 0.34 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Cogent Biosciences (COGT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cogent Biosciences (COGT), and what does it report?
Short answer · as of
Cogent does not sell products and generates no revenue.
Research dated 2026-09-13.
It is a development-stage company that executes research and clinical trials, burning through cash as it tests whether its targeted therapies work and are safe enough for regulatory approval.
The financial statements show research and development expenses as the primary operating cost, plus overhead for corporate and support functions. Without revenue, every metric—gross margin, operating margin, returns on assets—is negative by definition. The only metric that matters is cash runway and the likelihood that the lead program advances.
What do the latest results show for Cogent Biosciences (COGT)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Research dated 2026-09-13.
The company continues to report operating losses each quarter, as expected for an unfunded clinical-stage program. The operating cash burn rate has been steady, suggesting the company is executing its development timeline without major setbacks or accelerations.
There are no revenue or earnings surprises at a company with no revenue. The signal lies in whether the company announces clinical trial progress, regulatory meetings, or partnership achievements that reduce execution risk. Management guidance on cash runway is the most relevant metric.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
What are the financial strengths and risks for Cogent Biosciences (COGT)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The company maintains a substantial cash balance sufficient to fund operations for multiple years at the current burn rate. However, cash is finite; once depleted, the company must either achieve financing through equity issuance, debt, or partnership with a larger pharmaceutical company.
The risk is not imminent insolvency but dilution to shareholders if the company must raise capital at unfavorable terms. A major clinical setback could accelerate the burn rate, shortening runway. The company has debt, which would be senior to equity in a restructuring.
Data-derived red flags
- Negative return on equity (-99.6%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Cogent Biosciences (COGT)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $5.44M · EPS -2.33 · 7 analysts.
Research dated 2026-09-13.
Watch for announcements from the lead clinical trial: interim data results, dosing decisions, or regulatory feedback. Any material update is a catalyst for stock repricing and a signal of whether the program remains viable.
Monitor cash balance trends and any announcement of financing activity, partnership, or licensing arrangements. Such announcements would alter the runway calculation and capital structure.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for COGT.
Checked against the records this page reads, on the dates shown above.
How does Cogent Biosciences compare with its peers?
Short answer
Cogent Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Cogent differs from commercial pharma companies by having no approved products, no manufacturing scale, and no sales infrastructure. Its value depends entirely on the probability that its lead program succeeds and the estimated commercial opportunity if it does.
Against other clinical-stage biotech, Cogent's value relative to cash runway depends on the quality of its trial data and the magnitude of unmet medical need in its target populations. Investors are betting on clinical success probability and magnitude of future market opportunity, not on current operations.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $46.41 Nov 19, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $124.39 Nov 19, 2026 | $5.25B | 66 5-pillar Nov 18, 2026 | |
| $26.20 Nov 19, 2026 | $3.37B | 66 5-pillar Nov 18, 2026 | |
| Cogent Biosciences (COGT) — this page | $27.74 | $4.83B | 50 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $45.00 – $55.00
- Consensus target
- $50.67
- Median target
- $52.00
- Revenue estimate
- $5.44M
- EPS estimate
- $-2.33
Consensus record · Captured .
Measured against a quoted price of $27.74 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 14
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 2
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held COGT in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.16% | $7.08M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cogent Biosciences (COGT)?
Cogent Biosciences Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is CGT-something and why would it work?
Cogent's lead candidate is a targeted inhibitor designed to block a specific genetic mutation. The company has selected patients with the mutation and is testing whether blocking the target leads to clinical benefit. Success would mean regulators approve the drug and physicians prescribe it for patients with the mutation. Failure means the target either does not work or the drug is unsafe.
When will Cogent have revenue?
Revenue depends on whether the lead program gains regulatory approval and whether the company maintains the commercial rights (or partnerships with a larger firm to commercialize). Timeline estimates suggest potential approval and launch are years away. Analysts forecast revenue beginning in later fiscal periods, but these estimates depend on clinical trial success, which is inherently uncertain.
Should I buy this stock if I think the drug will work?
Stock price will largely track clinical trial progress and cash runway. If you are confident the drug will work, the question is valuation: whether current market price reflects fair odds of success and reasonable upside if it does. Biotech valuations are volatile; a single setback can halve the stock, and a strong trial result can double it. Position sizing matters more than conviction.
What is the dilution risk if the company needs to raise capital?
If Cogent must issue equity before the lead program launches, current shareholders will be diluted by the percentage that new shares represent. The magnitude depends on how much capital the company needs and at what valuation it can raise. Investors should monitor cash balance and management guidance on future capital needs to anticipate dilution likelihood and timing.
What is the COGT stock price today?
The last price recorded for Cogent Biosciences, Inc. (COGT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the COGT price target?
The analyst consensus price target for Cogent Biosciences, Inc. (COGT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com